Invivyd IVVD 深 沪
交易中 10-06 11:09:52 美东时间
0.8326
-0.007
-0.79%
华盛通- 最 高1.05
- 今 开0.8522
- 成交量 129.80万股
- 最 低 0.73
- 昨 收 0.8392
- 总市值 0
- 52周最高 3.0699
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 0.5277
- 委 比 -42.86%
- 总股本 --
- 历史最高 78.82
- 量 比 0.54
- 振 幅 38.13%
- 历史最低 0.355
- 每 手 1
- 风险率 0.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody
Invivyd reported Phase 3 LIBERTY trial data for VYD2311, showing strong safety and enhanced COVID-19 antibody levels.
09-30 02:44
BTIG Reiterates Buy on Invivyd, Maintains $10 Price Target
BTIG analyst Thomas Shrader reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $10 price target.
05-18 17:55
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program
Invivyd expands VYD2311 COVID study, delays timeline to Q3 2026, and advances measles antibody VMS063 toward clinical development.
04-09 22:07
Earnings Scheduled For March 5, 2026
Companies Reporting Before The Bell • Palladyne AI (NASDAQ:PDYN) is projected t...
03-05 19:11
Nasdaq Down 1%; Medtronic Earnings Top Views
U.S. stocks traded lower midway through trading, with the Dow Jones index falli...
2025-11-19 01:53
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
生物制药公司Invivyd将发行证券融资5000万美元
美股周四早盘，生物制药公司Invivyd（IVVD）股价重挫18%，此前该公司宣布通过证券发行筹集5000万美元资金。这笔融资将用于支持临床项目，包括针对长新冠的单克隆抗体疗法研究。 此次发行预计将于2025年8月22日完成，将为Invivyd的研发计划提供额外资源。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
2025-08-21 22:15
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus
Invivyd's CANOPY Phase 3 trial results show pemivibart provides strong protection (84% relative risk reduction) against symptomatic COVID-19 in a U.S. population, with safety and efficacy demonstrated in both immunocompromised and non-immunocompromised individuals. The findings support its emergency use authorization for pre-exposure prophylaxis in immunocompromised patients.
2025-05-27 11:01
Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19
<p>Invivyd commends FDA’s new approach to addressing uncertainties in COVID-19 booster efficacy and highlights its monoclonal antibody, pemivibart, which showed strong protection in trials. The company plans to advance next-generation antibodies and engage with FDA for expedited development to meet urgent needs for high-risk populations.</p>
2025-05-21 13:30
